Efavirenz to nevirapine switch in HIV-1 - Infected patients with dyslipidemia: A randomized, controlled study

Abstract

Many antiretroviral therapies, including efavirenz, are associated with increased serum concentrations of low-density lipoprotein cholesterol. In a small 52-week randomized study, we found that switching from efavirenz to nevirapine was associated with significantly decreased low-density lipoprotein cholesterol levels, compared with continuation of efavirenz therapy (P < .04). A switch to nevirapine was associated with no severe adverse events. © 2007 by the Infectious Diseases Society of America. All rights reserved.